GPT Healthcare Ltd Q1 FY27 Earnings Analysis
Published 24 May 2026 | Healthcare Services | Market Cap: ₹1.2K Cr
Price
₹140
Market Cap
₹1.2K Cr
P/E Ratio
28.6
Revenue Rank
Margin Rank
Earnings Summary
- Overall revenue growth expected at around 15% year-on-year for FY27 and FY28. - Mature hospitals (Salt Lake, Dum Dum, Agartala, Howrah) targeting occupancy improvements: - Salt Lake aiming for 70%-73% occupancy. - Dum Dum targeting around 72%-73% occupancy. - Agartala expected to reach 58%-60% occupancy, with Bangladesh patient contribution rising back to ~10%. - Howrah projected to achieve late 50% to 60% occupancy. - Raipur hospital targeting 30% occupancy by end of FY27 and expecting to breakeven by Q3 FY27. - Jamshedpur hospital expected to add approx. - FY27 revenue expected to grow by approximately 15% year-on-year.
📊 Revenue & Sales Performance
Rank 3- Overall revenue growth expected at around 15% year-on-year for FY27 and FY28. - Mature hospitals (Salt Lake, Dum Dum, Agartala, Howrah) targeting occupancy improvements: - Salt Lake aiming for 70%-73% occupancy. - Dum Dum targeting around 72%-73% occupancy. - Agartala expected to reach 58%-60% occupancy, with Bangladesh patient contribution rising back to ~10%. - Howrah projected to achieve late 50% to 60% occupancy. - Raipur hospital targeting 30% occupancy by end of FY27 and expecting to breakeven by Q3 FY27. - Jamshedpur hospital expected to add approx. 150 beds, with occupancy ramp-up similar to Raipur (~10%-14% in the first year). - ARPOB (Average Revenue Per Occupied Bed) expected to grow by about 7%-8% due to tariff increases and product optimization. - Anticipated 100 basis points increase in EBITDA margin, aiming around 20.2% EBITDA margin overall.
📈 Profitability & Margins
Rank 3- FY27 revenue expected to grow by approximately 15% year-on-year. - EBITDA margin anticipated to increase by around 100 basis points, targeting ~20.2%. - Raipur hospital expected to break even on a monthly basis by Q3 FY27. - ARPOB (Average Revenue Per Occupied Bed) forecasted to grow by 7-8% due to tariff increases and specialty optimization. - Occupancies expected to improve: Salt Lake around 70-73%, Dumdum ~72%, Agartala targeting 60%, Howrah late 50s to 60% by Q1 FY28, Raipur reaching 30% by Q4 FY27. - Jamshedpur hospital ramp-up expected to mirror Raipur with occupancy of ~10-14% in the first year. - Overall positive outlook on operating leverage improvement and sustainable profitability growth amid expanding geographic footprint and optimized specialty mix.
🏗️ Capital Expenditure Plans
Yes- Jamshedpur Hospital: Major capex to be deployed in FY27, approximately 90% of the total capex incurred in this financial year; remaining 10% mainly creditors-related. - Capex per bed for Jamshedpur: Around INR 70 lakhs per bed, similar to Raipur hospital. - Bed Addition: Targeting to add around 150 beds through Jamshedpur hospital commission by Q4 FY27. - M&A Strategy: Constantly evaluating suitable M&A opportunities in Eastern India, especially for hospitals around 150 to 200 beds. Focus on good real estate assets; no limitation on bed strength, but preference for mid-sized hospitals. - Overall Strategy: Evaluating both greenfield and acquisition opportunities post-Jamshedpur to expand portfolio. - Raipur: Commissioned in FY26, breakeven expected by Q3 FY27 with ramp-up in occupancy and insurance empanelments expected to improve.
💰 Fundraising & Capital Structure
No information- No explicit mention of any new fundraising through debt or equity in the Q4 FY26 earnings call transcript. - The management discussed capital expenditure plans, particularly on Jamshedpur hospital, with ~90% capex expected in FY27 and minimal carryover for next year. - They emphasized disciplined capital allocation and are focused on improving operational performance and sustainable growth. - Management is actively evaluating M&A opportunities, especially for hospitals around 150-200 beds, but no details on raising funds for these. - No reference to plans for equity issuance or new debt for expansion or refinancing was provided in the discussed sections. - Overall, the company appears to be funding growth primarily through internal accruals and existing financial resources.
📋 Order Book & Pipeline
No informationThe provided transcript and document do not explicitly mention current or expected order book or pending orders for GPT Healthcare Limited. The discussion primarily focuses on: - Hospital occupancy rates and specialty mix at various locations. - Revenue and EBITDA guidance for FY27 and FY28. - Expansion plans including bed additions, notably 150 beds targeted through the Jamshedpur hospital. - Expectations on occupancy ramp-up and ARPOB growth. - Evaluation of M&A opportunities targeting hospitals around 150-200 beds. - Strategic focus on underserved markets in Eastern and Central India. No direct reference to an order book or pending order values is provided in the transcript.
Key Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were GPT Healthcare Ltd Q1 FY27 results?
- Overall revenue growth expected at around 15% year-on-year for FY27 and FY28. - Mature hospitals (Salt Lake, Dum Dum, Agartala, Howrah) targeting occupancy improvements: - Salt Lake aiming for 70%-73% occupancy. - Dum Dum targeting around 72%-73% occupancy. - Agartala expected to reach 58%-60% occupancy, with Bangladesh patient contribution rising back to ~10%. - Howrah projected to achieve late 50% to 60% occupancy. - Raipur hospital targeting 30% occupancy by end of FY27 and expecting to breakeven by Q3 FY27. - Jamshedpur hospital expected to add approx. - FY27 revenue expected to grow by approximately 15% year-on-year.
What is GPT Healthcare Ltd share price analysis?
GPT Healthcare Ltd currently shows a below-average growth signal. The stock trades at a P/E of 28.6 with a market cap of ₹1,161. Investors should review the full earnings analysis for detailed insights.
Is GPT Healthcare Ltd planning capital expenditure?
- Jamshedpur Hospital: Major capex to be deployed in FY27, approximately 90% of the total capex incurred in this financial year; remaining 10% mainly creditors-related.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
